ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma.
Liangliang ZhangOmar HamdaniOle V GjoerupCheryl Cho-PhanJeremy SniderEmily H CastellanosHalla NimeiriGarrett M FramptonJeffrey M VenstromGeoffrey R OxnardSamuel J KlempnerAlexa B SchrockPublished in: JCO precision oncology (2022)
CN, particularly in the setting of the evolving anti-HER2 landscape and combination therapies, are warranted.
Keyphrases
- epidermal growth factor receptor
- copy number
- tyrosine kinase
- mitochondrial dna
- advanced non small cell lung cancer
- endothelial cells
- genome wide
- squamous cell carcinoma
- high resolution
- dna methylation
- lymph node metastasis
- type diabetes
- pluripotent stem cells
- radiation therapy
- locally advanced
- mass spectrometry
- single cell
- metabolic syndrome
- skeletal muscle
- glycemic control